{"title":"变革的催化剂?孤儿药和Catalyst诉Becerra案","authors":"Paul A. Braier","doi":"10.1177/17411343221116086","DOIUrl":null,"url":null,"abstract":"CompiledandwrittenbyGreenblum&BernsteinPLC A US intellectual property law firm which provides a full range of services in IP-related matters across all industries, including the biotech and pharmaceutical industries, including: Inter partes Review (IPR) and Post Grant Review (PGR) Abbreviated new drug applications (ANDAs) and Notice Letters Patent and trademark litigation Patent drafting and prosecution Patent infringement and validity opinions Patent reexamination proceedings and interferences New drug strategies Market entry strategies Joint venture strategies Licensing This section is intended to be a synopsis of recent developments and is not intended to be exhaustive. If any issue referred to in this section is to be relied upon, specific advice should be sought. Please contact: Paul A. Braier, PhD, Esq. Greenblum & Bernstein PLC 1950 Roland Clarke Place Reston, VA 20191 USA Tel: +1 703 716 1191 Fax: +1 703 716 1180 Email: pbraier@gbpatent.com Web: www.gbpatent.com","PeriodicalId":15914,"journal":{"name":"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector","volume":"70 1","pages":"194 - 197"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A catalyst for change? Orphan drugs and the case of Catalyst v. Becerra\",\"authors\":\"Paul A. Braier\",\"doi\":\"10.1177/17411343221116086\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"CompiledandwrittenbyGreenblum&BernsteinPLC A US intellectual property law firm which provides a full range of services in IP-related matters across all industries, including the biotech and pharmaceutical industries, including: Inter partes Review (IPR) and Post Grant Review (PGR) Abbreviated new drug applications (ANDAs) and Notice Letters Patent and trademark litigation Patent drafting and prosecution Patent infringement and validity opinions Patent reexamination proceedings and interferences New drug strategies Market entry strategies Joint venture strategies Licensing This section is intended to be a synopsis of recent developments and is not intended to be exhaustive. If any issue referred to in this section is to be relied upon, specific advice should be sought. Please contact: Paul A. Braier, PhD, Esq. Greenblum & Bernstein PLC 1950 Roland Clarke Place Reston, VA 20191 USA Tel: +1 703 716 1191 Fax: +1 703 716 1180 Email: pbraier@gbpatent.com Web: www.gbpatent.com\",\"PeriodicalId\":15914,\"journal\":{\"name\":\"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector\",\"volume\":\"70 1\",\"pages\":\"194 - 197\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/17411343221116086\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17411343221116086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
greenblum&bernsteinplc是一家美国知识产权律师事务所，为包括生物技术和制药行业在内的所有行业提供全方位的知识产权相关服务，包括:专利和商标诉讼专利起草和审查专利侵权和有效性意见专利复审程序和干扰新药战略市场进入战略合资企业战略许可本节旨在概述最近的发展，但并非详尽。如果要依赖本节中提到的任何问题，应寻求具体的建议。请联系:Paul A. Braier, PhD, Esq。Greenblum & Bernstein PLC 1950 Roland Clarke Place Reston, VA 20191 USA电话:+1 703 716 1191传真:+1 703 716 1180邮箱:pbraier@gbpatent.com网址:www.gbpatent.com
A catalyst for change? Orphan drugs and the case of Catalyst v. Becerra
CompiledandwrittenbyGreenblum&BernsteinPLC A US intellectual property law firm which provides a full range of services in IP-related matters across all industries, including the biotech and pharmaceutical industries, including: Inter partes Review (IPR) and Post Grant Review (PGR) Abbreviated new drug applications (ANDAs) and Notice Letters Patent and trademark litigation Patent drafting and prosecution Patent infringement and validity opinions Patent reexamination proceedings and interferences New drug strategies Market entry strategies Joint venture strategies Licensing This section is intended to be a synopsis of recent developments and is not intended to be exhaustive. If any issue referred to in this section is to be relied upon, specific advice should be sought. Please contact: Paul A. Braier, PhD, Esq. Greenblum & Bernstein PLC 1950 Roland Clarke Place Reston, VA 20191 USA Tel: +1 703 716 1191 Fax: +1 703 716 1180 Email: pbraier@gbpatent.com Web: www.gbpatent.com
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
